News centre | United Kingdom

February 20, 2018

Philips launches Lumify app-based ultrasound solution in the UK, for point-of-care diagnostics across care settings

 

  • Smart device solution uses Android tablet interface for ultra-mobile, flexible use at point of care
  • Three advanced ultrasound transducers, and comprehensive app-based software suite offer clinicians enhanced diagnostic care whenever and wherever they need it

Guildford, the UK – Royal Philips (NYSE: PHG, AEX: PHIA) a globally leading heath technology company, has announced that Lumify, a smart device ultrasound solution for use at the point of care, is available in the UK. Philips’ new ultrasound digital health device connects off-the-shelf compatible smart devices, a mobile application, advanced ultrasound transducer technology, integrated IT and support services to help healthcare providers improve patient care while potentially reducing ultrasound associated costs.

 

Point of Care Ultrasound in Emergency Care

In the emergency and acute setting the ability to quickly offer ultrasound at the patient side provides considerable care benefits

Rob Galloway

Emergency Medicine Consultant Brighton and Sussex Hospital NHS Trust

“Having immediate access to a smart tablet device reduces the time needed to start ultrasound diagnostics and means we can accurately assess our patients’ condition, make quick critical decisions and shorten the time to the right treatment.”

 

Since debuting the smart device ultrasound concept in 2014, Philips has enhanced the solution for increasing clinical uses including acute, non-emergency, sports and primary care practices. With three transducers including sector, linear and curved array for a variety of scans, Lumify provides clinicians with the ability to carry out informed assessments across procedures such as cardiac, pararentesis, thyroid, lung and abdomen exams, obstetric examinations and line placements.

“Having Lumify in the UK is a great tool to help clinicians deliver diagnostic excellence in a cost effective way,” comments Randy Hamlin, Business Leader Point of Care for Philips. “With the ultrasound technology living in the transducer, clinicians can connect Lumify to any compatible smart device for immediate access to industry-leading mobile ultrasound images. It also connects easily into existing hospital IT and PACS systems so it’s perfectly attuned to today’s demands for seamless care and image access, to ensure care teams can meet growing demands while driving improved patient satisfaction.”

 

Ultimate Patient Care, Where You Need It, When You Need It

Lumify is a solution that will grow with its users, with plans for regular software updates and additional transducers, services and apps released at regular intervals. By providing a versatile and flexible point-of-care digital ultrasound system, Philips Lumify is designed to support clinicians across a variety of care settings to provide the best patient care where it’s needed and when it’s needed.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read moreClick here to read less

Topics

Contacts

Media assets

Press releases

Get our press releases by e-mail

You are about to visit a Philips global content page

Continue

Share on social media

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.